Arrow Clinical Trials

02/11/2026

❤️ February is American Heart Month.
Heart disease impacts millions—but research drives progress.
Clinical trials help uncover better prevention, earlier detection, and smarter treatments.
If you’ve ever wondered how new heart therapies come to life, this is where it starts.

Learn more about participating in research.

02/02/2026

Read this inspiring interview with our own CEO Dr. David Billmeier, who is passionate about treating neurodegenerative diseases.

For families facing life-altering diagnoses such as Alzheimer’s or Parkinson’s disease, the search for answers can feel overwhelming. In those moments, access to trusted information — and a place to

01/29/2026

This article discusses the fact that there are no effective treatments for agitation and psychosis in Dementia.
In an effort to address the desperation expressed by caregivers and care facilities, physicians frequently prescribe anti-psychotic medications that have no proven benefit and are otherwise none to have potential for harm.

Our studies offer an alternative to this solution to this desperation with greater medical safety oversight. Reach out to learn more.

When agitated dementia patients wander or shout through the night, families and caregivers understandably feel the need to treat this frightening and potentially dangerous behavior. Antipsychotic medications are often resorted to with such patients, contributing to increases in antipsychotic treatme...

01/23/2026

Come see what available at the Senior Expo 548 N Nova Road and say hello to Arrow Clinical Trials.

01/22/2026

View the Port Orange for Thursday, January 22, 2026

01/22/2026

Come and visit us at the Hometown News Volusia Lifestyle and Wellness Expo on Wednesday, January 28th at the Sunshine Park Plaza in South Daytona and visit our Community Ambassador Shawn Geopfert, who is also interviewed in this article on behalf of Arrow Clinical Trials

View the Port Orange for Thursday, January 22, 2026

01/15/2026

Our team was fortunate to be part of this important study. We appreciate the collaboration and the opportunity to contribute to research that advances patient care.

Sleep apnea affects as many as 80 million in the U.S. Now Apnimed, the $400 million company behind the first ever pill to treat it, is preparing to file for FDA approval.

01/13/2026

High Lp(a) in Women: What It Means for Long-Term Heart Health — A New Study Opportunity Coming at Arrow Soon

Very high lipoprotein(a) levels predict 30‑year cardiovascular risk in healthy women

https://www.epocrates.com/online/contextuallink/article/very-high-lipoprotein-a-levels-predict-30-year-cardiovascular-risk-in?utm_source=share&utm_medium=member_web

01/05/2026

Advancing Heart Health Close to Home: We’re Preparing for a New Lipoprotein(a) Heart Health Study

High levels of lipoprotein(a) often go undetected and can afflict seemingly healthy people. A clinical trial will show whether lowering levels can reduce risk of heart disease.

12/12/2025

12/04/2025

Emerging insights from leading metabolic experts, including our own CMO Dr. Charles Ross, highlight a growing concern around GLP-1 medications: while they effectively support weight reduction, they may also accelerate muscle loss when not paired with the right strategy. As more patients turn to GLP-1 therapies, understanding how these drugs influence muscle health—and what can be done to protect strength and long-term function—has become essential.

Learn how Ozempic, Mounjaro, diet, and exercise affect muscle loss, and discover how protein and resistance training help preserve strength during weight loss.